RadioMedix

20 articles about RadioMedix

• RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors First Targeted Alpha Therapy to receive a Breakthrough Therapy Designation

  2/12/2024

  RadioMedix, Inc. and Orano Med announced that the United States Food and Drug Administration has granted Breakthrough Therapy Designation to AlphaMedixTM for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors who are naïve to peptide receptor radionuclide therapy.

• RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

  5/16/2023

  RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE.

• RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.

  2/15/2023

  RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals.

• RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology;

  10/7/2022

  RadioMedix, Inc., a clinical-stage biotechnology company announced an agreement with an entity related to Portland Investment Counsel Inc. involving an equity investment of $40 million Series A funding round.

• Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers

  1/3/2022

  RadioMedix and Orano Med are pleased to announce the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the first patient on December 21st , 2021. 

• RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY

  11/18/2021

  RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health.

• Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme

  7/8/2021

  Vect-Horus and RadioMedix are pleased to announce the FDA clearance of exploratory Investigational New Drug (eIND) application to evaluate 68 Ga-RMX-VH for the detection and mapping of Low Density Lipoprotein Receptor (LDLR) overexpressed in Glioblastoma Multiforme (GBM).

• RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit

  1/4/2021

  RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for the 2020 TechConnect Innovation Award.

• RadioMedix appointed Dr.Ferey Faridian as new member of the Board of Director

  10/13/2020

  Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer, announced the appointment of Dr. Ferey Faridian as a member of its Board of Directors.

• ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. Market

  7/10/2020

  ITM Isotopen Technologien München AG and RadioMedix Inc. announced that ITM has filed a Drug Master File with the U.S. Food and Drug Administration for ITM’s next generation Germanium-68/Gallium-68 Generator, which is manufactured at the RadioMedix Spica Center in Houston, Texas, U.S. and distributed under the brand name GeGant®.

• RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)

  1/3/2020

  RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program by the National Institute of Health SBIR/STTR program office.

• Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

  10/14/2019

  Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.

• Vect-Horus and RadioMedix Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

  3/5/2019

  This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals.

• RadioMedix and ITM Announce Agreement for Manufacturing of Ge-68/Ga-68 Generators in U.S.

  7/26/2018

  RadioMedix Inc. and ITM Isotopen Technologien München (ITM) announced today that ITM’s subsidiary, Isotope Technologies Garching GmbH (ITG), and RadioMedix have signed a manufacturing and supply agreement for the production of the next generation of Ge-68/Ga-68

• Radiomedix and AREVA Med Announce Initiation of Phase I Clinical Trial of Alphamedix, a Targeted Alpha Therapy for Patients With Neuroendocrine Tumors

  1/10/2018

  Patients will be enrolled at Excel Diagnostic and Nuclear Oncology Center (Houston, TX).

• RadioMedix Selected for National Cancer Institute's Investor Initiatives and Presentation at BIO Investor Forum

  10/17/2017

  t is a unique opportunity to present pipeline of RadioMedix products and offer clinical and R&D services to biopharma experts and investors.

• Extended Partnership Between RadioMedix And ITM´s Subsidiary ITG For Exclusive Distribution Of N.C.A Lutetium-177 In North America

  10/11/2017

• RadioMedix Release: First U.S. Multi-Center Investigational Clinical Trial Of 177 Lu PSMA-617 Targeted Radioligand Therapy In Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

  2/6/2017

• RadioMedix And AREVA Med – SBIR NCI Contract Grant Awarded To Develop Targeted Alpha-Emitter Therapy Of Neuroendocrine Tumors With Lead-212

  11/1/2016

• RadioMedix Successfully Completed The Phase I/ II Clinical Studies For Aminomedix Used For Radiation Kidney Protection During Peptide-Receptor Radionuclide Therapy (PRRT)

  10/20/2016